CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 36 enrolled
Drug / intervention
GIP-infusion +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

In the news

12 articles

Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.

Search/NCT01880827
NCT01880827Phase 1Completed
CompareCT.gov

The Effects of Glucose-dependent Insulinotrophic Peptide (GIP) and Glucagon-like Peptide 1 (GLP-1) on Splanchnic Redistribution of Blood Flow at Postprandial State and After Roux-en-Y Gastric Bypass and Sleeve

Turku University Hospital·interventional·Posted Jun 19, 2013·Updated Oct 20, 2021

In Brief

A Phase 1 clinical trial evaluating Roux-en-Y, GIP-infusion, and 3 other interventions for Type 2 Diabetes and Obesity. Completed, enrolled 36 participants across 1 site.

Detailed Summary

Obesity is a worldwide problem and leads to multiple metabolic and endocrinological problems. Bariatric surgeries are a growing field as a treatment choice for morbid obesity (BMI \> 35 kg/m2). Clinical and research evidence shows that shortly after RYGB, T2DM resolves with improving glucose tolerance. Foregut hypothesis behind bariatric surgeries postulate, that bypassed portions of intestine contain a substance, that acts as an anti-incretin, ie. to counteract metabolically favourable incretins. In view of the recent studies, it may be that GIP is really the anti-incretin behind this hypothesis. The current study is conducted to investigate the vasoactive roles of the GIP. The investigators aim to show that GIP is the major contributor to the blood flow and tissue blood volume observed in postprandial state.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes, Obesity
CountriesFinland
CollaboratorsLund University

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 19, 2013
Enrollment StartJan 1, 2013
Primary CompletionNov 1, 2015
Study CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 13.0 years ago

Interventions

Roux-en-Yprocedure

Subjects in the intervention group will be divided into two consecutive surgical groups, RYGB or SG. After the surgery, subjects are controlled in hospital ward for approximately three days.

GIP-infusiondrug

Blood flow and volume during infusion

GLP-1drug

Blood flow and volume during infusion

MMSdrug

Blood flow and volume after meal solution

Sleeve gastrectomyprocedure

as in RYGS group